ClinicalTrials.gg
RecruitingNCT05050903Updated Apr 24, 2024

Early Antiviral Responses to Rhinovirus Infection in Asthma

An observational study in Asthma, sponsored by Imperial College London. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-24.

Sponsored by Imperial College London · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2025, 1 year 2 months ago, but the record still lists the study as recruiting.
  • Started Aug 2022; still recruiting 4 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
40
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Asthma by Imperial College London — 4 open to participants now, 4 under way, none of them phase 3. Asthma · Imperial College London.

Planned enrollment
12th of 17
40 · median 66
Started
2022
the only one that year
Observational
17 of 46
4 open now
Registered
44th of 46
by date

Among the 46 studies in Asthma by Imperial College London, this one is the 12th largest by planned enrollment of the 17 observational ones that give a count, is the only one that started in 2022, is one of 17 observational ones, and was the 44th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

4 of the 46 studies in Asthma by Imperial College London are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Asthma by Imperial College London, or all of them as a file.
02

Study summary

The bulk of the morbidity and mortality related to asthma is during periods of acutely increased symptomatology called 'exacerbations'. Roughly half of asthma sufferers experience such an exacerbation each year. Most of these events are triggered by viral infections, usually the common cold virus (rhinovirus).

A key part of the body's defence against viral infections is to produce antiviral proteins called 'interferons', which have a myriad of effects to stop viruses. Previous work on cells taken from volunteers with asthma and healthy controls and infected with rhinovirus in the lab suggests interferon production is impaired in asthma. However when human volunteers with asthma are infected with rhinovirus, high levels of interferon are found a few days later - along with high numbers of virus. Whether the high virus numbers are the result of an initially weak interferon response, with subsequently unchecked viral replication leading to exaggerated interferon levels, is unknown as no one has measured interferons early in infection.

By infecting volunteers with asthma and healthy controls with rhinovirus at a known time, only done in a handful of centres worldwide, we will be able to measure interferons within hours of infection and well before symptoms develop.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Potential participants will be identified from hospital outpatient clinics, primary care, spirometry sessions/clinics, other research projects, and advertisements.

Eligibility criteria

For Asthma group:

Inclusion Criteria:

  • Age 18-55 years
  • Doctor diagnosis of asthma
  • Previous asthma exacerbation

Exclusion Criteria:

  • Smoking history over past 12 months
  • Sinonasal disease, including current symptoms of allergic rhinitis
  • Asthma exacerbation or an upper respiratory viral infection within the previous six weeks
  • Current or concomitant use of oral , monoclonal antibodies or nasal sprays
  • Neutralising antibodies to rhinovirus (RV)-16
  • diseases other than asthma which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, influence the results of the study, an/or the patient's ability to take part in it
  • Inability to understand written or verbal information in English

For healthy control group:

Inclusion Criteria:

  • Age 18-55 years

Exclusion Criteria:

As for Asthma group and in addition:

  • History of asthma
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Asthma

    Other: Rhinovirus infection

  • Healthy controls

    Other: Rhinovirus infection

Interventions

  • OtherRhinovirus infection

    Inoculation with rhinovirus-16

06

What researchers measure

Primary outcomes

  1. Nasal IFN-λ at 6 hours post rhinovirus infection

    Difference in IFN-λ in nasal lining fluid 6 hours following rhinovirus infection in subjects with asthma compared to healthy controls

    Time frame: 6 hours

Secondary outcomes

  1. Nasal IFN-α at 6 hours post rhinovirus infection

    Difference in IFN-α in nasal lining fluid 6 hours following rhinovirus infection in subjects with asthma compared to healthy controls

    Time frame: 6 hours

  2. Nasal IFN-λ at 3 hours post rhinovirus infection

    Difference in IFN-λ in nasal lining fluid 3 hours following rhinovirus infection in subjects with asthma compared to healthy controls

    Time frame: 3 hours

  3. Nasal IFN-λ at 24 hours post rhinovirus

    Difference in IFN-λ in nasal lining fluid 24 hours following rhinovirus infection in subjects with asthma compared to healthy controls

    Time frame: 24 hours

  4. Nasal IFN-α at 3 hours post rhinovirus infection

    Difference in IFN-α in nasal lining fluid 3 hours following rhinovirus infection in subjects with asthma compared to healthy controls

    Time frame: 3 hours

  5. Nasal IFN-α at 24 hours post rhinovirus infection

    Difference in IFN-α in nasal lining fluid 24 hours following rhinovirus infection in subjects with asthma compared to healthy controls

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • Imperial College Respiratory Research Unit, St Mary's Hospital
    London, Greater London W2 1NY, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2022 (actual). Primary completion is estimated for Aug 2025, 36 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 36 months is close to that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2021
First posted
Sep 21, 2021
StartActual
Aug 11, 2022
Primary completionEst.
Aug 31, 2025
CompletionEst.
Aug 31, 2025
Last update
Apr 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05050903
Responsible party
Sponsor
First posted
Sep 21, 2021
Start date
Aug 11, 2022
Primary completion
Aug 31, 2025 (estimated)
Completion
Aug 31, 2025 (estimated)
Last update
Apr 24, 2024

Study contacts

Research Fellow
Contact
imperial.magic@nhs.net
020 7594 3751
Sebastian Johnston
principal investigator · Imperial College London

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion